Country: Իռլանդիա
language: անգլերեն
source: HPRA (Health Products Regulatory Authority)
VENLAFAXINE
WPR Healthcare Limited
N06AX16
VENLAFAXINE
75 Milligram
Prolonged Release Capsules
Product subject to prescription which may not be renewed (A)
Other antidepressants
Authorised
2011-06-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Venlofex 75mg prolonged-release capsules, hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release capsule, contains venlafaxine hydrochloride equivalent to 75mg of venlafaxine For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Prolonged release capsules, hard _Product imported form the UK:_ Opaque, flesh prolonged release capsules, hard, marked with ‘VEN’ on one side of the capsule and ‘75’ on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder Treatment of panic disorder, with or without agoraphobia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Major depressive episodes: The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days. Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained. Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence read_full_document